Based on poor prospects for profits and increased safety concerns of anemia drugs in general, Neose Technologies Inc. is discontinuing development of its erythropoiesis-stimulating agent (ESA), NE-180 (GlycoPEGylated erythropoietin). (BioWorld Today)
Based on poor prospects for profits and increased safety concerns of anemia drugs in general, Neose Technologies Inc. is discontinuing development of its erythropoiesis-stimulating agent (ESA), NE-180 (GlycoPEGylated erythropoietin). (BioWorld Today)
Study results showed that Acorda Therapeutics Inc.'s multiple sclerosis drug Fampridine-SR does not increase a patient's risk of developing cardiac arrhythmias, or an irregular heart beat. (BioWorld Today)
